Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma.

Cancer Cell Int · 2022 · PMC8858483 · PMID 35183162

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, our data showed a trend for reduced survival in patients with high levels (> 40%) of Nestin expression in their initial tumor.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.